Published in World J Gastroenterol on June 21, 2011
The hallmarks of cancer. Cell (2000) 113.05
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med (2004) 30.26
K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med (2008) 27.35
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med (2006) 26.37
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med (2007) 24.19
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med (2001) 18.77
Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med (2008) 12.97
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature (2007) 10.94
Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer (1998) 10.17
PI3K pathway alterations in cancer: variations on a theme. Oncogene (2008) 9.94
Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet (2002) 8.46
Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature (2008) 7.10
Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol (2004) 6.61
Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol (1997) 5.89
Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med (2005) 4.52
MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res (2002) 3.97
The protein tyrosine kinase family of the human genome. Oncogene (2000) 3.48
The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res (2006) 3.17
Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res (2009) 3.14
Receipt of previous diagnoses and endoscopy and outcome from esophageal adenocarcinoma: a population-based study with temporal trends. Am J Gastroenterol (2009) 3.04
Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol (2006) 3.00
Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol (2007) 2.69
Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol (2006) 2.61
Fluorouracil: biochemistry and pharmacology. J Clin Oncol (1988) 2.46
Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res (2002) 2.46
The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: a systematic review and meta-analysis. Am J Epidemiol (2008) 2.34
Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol (2006) 2.33
Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol (2006) 2.19
Transforming ras genes from human melanoma: a manifestation of tumour heterogeneity? Nature (1984) 2.14
Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol (1998) 2.11
Effect of a prior endoscopy on outcomes of esophageal adenocarcinoma among United States veterans. Gastrointest Endosc (2008) 1.96
Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux. Gut (2004) 1.92
The Ras-MAPK signal transduction pathway, cancer and chromatin remodeling. Biochem Cell Biol (2005) 1.79
Low prevalence of submucosal invasive carcinoma at esophagectomy for high-grade dysplasia or intramucosal adenocarcinoma in Barrett's esophagus: a 20-year experience. Gastrointest Endosc (2009) 1.73
Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer (2001) 1.65
Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance. Cancer Lett (2006) 1.53
Relationship between Helicobacter pylori infection and esophageal neoplasia: a meta-analysis. Clin Gastroenterol Hepatol (2007) 1.49
Taxol: the first of the taxanes, an important new class of antitumor agents. Semin Oncol (1992) 1.43
A 4-gene signature predicts survival of patients with resected adenocarcinoma of the esophagus, junction, and gastric cardia. Gastroenterology (2010) 1.43
Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. J Clin Oncol (2006) 1.34
Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. Ann Oncol (2004) 1.34
Genetic analysis of human esophageal tumors from two high incidence geographic areas: frequent p53 base substitutions and absence of ras mutations. Cancer Res (1991) 1.32
The epidemic of esophageal adenocarcinoma. Gastroenterol Clin North Am (2002) 1.29
A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response. Clin Cancer Res (2007) 1.28
Expression and prognostic relevance of activated extracellular-regulated kinases (ERK1/2) in breast cancer. Br J Cancer (2005) 1.22
Trends in oesophageal and gastric cancer incidence, mortality and survival in England and Wales 1971-1998/1999. Aliment Pharmacol Ther (2003) 1.22
Alterations of the Wnt signaling pathway during the neoplastic progression of Barrett's esophagus. Oncogene (2006) 1.22
Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy. Br J Cancer (2003) 1.22
Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer. Br J Cancer (2003) 1.13
Mutation analysis of PIK3CA and PIK3CB in esophageal cancer and Barrett's esophagus. Int J Cancer (2006) 1.13
Clinical significance of insulin-like growth factor type 1 receptor and epidermal growth factor receptor in patients with advanced gastric cancer. Oncology (2008) 1.11
Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy. Clin Cancer Res (2003) 1.10
Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma. Int J Radiat Oncol Biol Phys (2006) 1.08
Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials. Anticancer Drugs (2010) 1.07
Met expression is an independent prognostic risk factor in patients with oesophageal adenocarcinoma. Br J Cancer (2008) 1.06
Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma. Br J Cancer (2007) 1.05
Targeting the epidermal growth factor receptor by erlotinib (Tarceva) for the treatment of esophageal cancer. Int J Cancer (2006) 1.04
The ERK MAP kinase-PEA3/ETV4-MMP-1 axis is operative in oesophageal adenocarcinoma. Mol Cancer (2010) 1.03
Impaired transforming growth factor beta signalling in Barrett's carcinogenesis due to frequent SMAD4 inactivation. Gut (2005) 1.03
Sorafenib triggers antiproliferative and pro-apoptotic signals in human esophageal adenocarcinoma cells. Dig Dis Sci (2008) 0.99
Involvement of MMP-7 in invasion of pancreatic cancer cells through activation of the EGFR mediated MEK-ERK signal transduction pathway. J Clin Pathol (2005) 0.97
A prospective comparison of multidisciplinary treatment of oesophageal cancer with curative intent in a UK cancer network. Eur J Surg Oncol (2006) 0.94
Leptin synergistically enhances the anti-apoptotic and growth-promoting effects of acid in OE33 oesophageal adenocarcinoma cells in culture. Mol Cell Endocrinol (2007) 0.93
RNA interference as a gene-specific approach for molecular medicine. Curr Med Chem (2005) 0.92
Expression and roles of keratinocyte growth factor and its receptor in esophageal cancer cells. Int J Oncol (2007) 0.91
Clinical significance of VEGF-A, -C and -D expression in esophageal malignancies. Onkologie (2005) 0.90
Targeting the Wnt signaling pathway to treat Barrett's esophagus. Expert Opin Ther Targets (2007) 0.89
Chenodeoxycholic acid stimulates the progression of human esophageal cancer cells: A possible mechanism of angiogenesis in patients with esophageal cancer. Int J Cancer (2006) 0.89
Modification of insulin-like growth factor 1 receptor, c-Src, and Bcl-XL protein expression during the progression of Barrett's neoplasia. Hum Pathol (2003) 0.89
Co-expression of receptor tyrosine kinases in esophageal adenocarcinoma and squamous cell cancer. Oncol Rep (2008) 0.88
Significance of chromosome change to hematopoietic neoplasms. Blood (1983) 0.87
Mitogen-activated protein kinases (MAPK) as predictors of clinical outcome in serous ovarian carcinoma in effusions. Gynecol Oncol (2003) 0.86
Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer. Br J Cancer (2008) 0.86
Potential role of NF-kappaB in esophageal adenocarcinoma: as an emerging molecular target. J Surg Res (2008) 0.85
Targeting MEK is effective chemoprevention of hepatocellular carcinoma in TGF-alpha-transgenic mice. J Gastrointest Surg (2007) 0.84
Neurotrophic receptor, tropomyosin-related kinase B, as a chemoresistant marker in oesophageal cancer. Clin Oncol (R Coll Radiol) (2009) 0.81
Anthracyclines. Cancer Chemother Biol Response Modif (1990) 0.79
A phase II study of doxorubicin, cisplatin, and 5-fluorouracil in patients with advanced adenocarcinoma of the stomach or esophagus. Cancer Invest (2006) 0.79
Gastric antral vascular ectasia (GAVE): an update on clinical presentation, pathophysiology and treatment. Digestion (2008) 1.52
The ERK MAP kinase-PEA3/ETV4-MMP-1 axis is operative in oesophageal adenocarcinoma. Mol Cancer (2010) 1.03
Targeting the cell cycle in esophageal adenocarcinoma: an adjunct to anticancer treatment. World J Gastroenterol (2011) 0.87
Overview of bariatric surgery for the physician. Clin Med (2012) 0.80
Risk factors for neoplastic progression in Barrett's esophagus. World J Gastroenterol (2011) 0.77
Biomarkers of normal tissue toxicity after pelvic radiotherapy. Curr Opin Support Palliat Care (2012) 0.77